Mr. Amlani continued, "We believe the Vevo LAZR system will have a strong impact on the discovery of new cancer therapies in the pre-clinical market space and that we will see a translation of these discoveries into practical applications in humans. With a healthy set of pre-ordered systems, we are anticipating strong product demand."
"The launch of this 'new to the world' technology keeps VisualSonics at the forefront of imaging advancements for life-sciences research," said Kevin M. Goodwin, SonoSite President and CEO. "We are excited that SonoSite and VisualSonics have joined forces to innovate and deliver new breakthrough imaging technologies and we are pleased with the initial customer demand for the new product."
Ad Statistics
Times Displayed: 50077
Times Visited: 1414 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
The Vevo LAZR system supports VisualSonics' continuous efforts to provide researchers with innovative solutions to improving pre-clinical research. The core of the Vevo LAZR technology is the LZ® Series integrated fiber-optic linear array transducers with microbeamforming technology. Harnessing the sensitivity of 256 active elements, the LZ Series transducer provides clear and high-resolution images - in both 2D and 3D modes. Applications for the Vevo LAZR system range from lymph node imaging, study of hemoglobin and oxygen saturation, and targeted imaging of tumor biomarkers. In addition to cancer biology, this cutting-edge imaging system will benefit other areas of research such as diabetes, neurosciences, as well as developmental and reproductive biology.
Researchers are invited to experience a demonstration of the Vevo LAZR system by visiting VisualSonics at booth #2171 at AACR.
About VisualSonics
VisualSonics is the world leader in real-time, in vivo, high-resolution micro-imaging systems designed specifically for preclinical research and a wholly-owned subsidiary of SonoSite, Inc. (Nasdaq:Sono). The Company's cutting-edge technologies allow researchers at the world's most prestigious pharmaceutical and biotechnology companies, hospitals and universities to conduct research in cardiovascular, cancer, neurobiology and developmental biology areas. The micro-imaging technologies support research applications that include genetic research, phenotypic studies and drug development. VisualSonics micro-imaging platforms combine high-resolution, real-time in vivo imaging at reasonable cost with ease-of-use and quantifiable results.
About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world leader in bedside and point-of-care ultrasound and an industry leader in ultra high-frequency micro-ultrasound technology and impedance cardiography equipment. Headquartered near Seattle, the company is represented by fourteen subsidiaries and a global distribution network in over 100 countries. SonoSite's small, lightweight systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care.
